Immunetics, Inc.
Boston, MA 02210
Blood Platelet Analyzer determines bacterial contamination.
Designed for use with BacTx rapid test for bacteria in whole-blood derived and apheresis platelets, BacTx-® Analyzer offers automated interpretation, tracking, and documentation. Features increase transfusion patient safety while also providing seamless integration with laboratory workplace. Providing automation and workflow-enhancement features, analyzer delivers complete assay results and...
Read More »Blood Platelet Analyzer determines bacterial contamination.
Designed for use with BacTx rapid test for bacteria in whole-blood derived and apheresis platelets, BacTx-® Analyzer offers automated interpretation, tracking, and documentation. Features increase transfusion patient safety while also providing seamless integration with laboratory workplace. Providing automation and workflow-enhancement features, analyzer delivers complete assay results and...
Read More »Blood Platelet Analyzer determines bacterial contamination.
Designed for use with BacTx rapid test for bacteria in whole-blood derived and apheresis platelets, BacTx-® Analyzer offers automated interpretation, tracking, and documentation. Features increase transfusion patient safety while also providing seamless integration with laboratory workplace. Providing automation and workflow-enhancement features, analyzer delivers complete assay results and...
Read More »Blood Platelet Analyzer determines bacterial contamination.
Designed for use with BacTx rapid test for bacteria in whole-blood derived and apheresis platelets, BacTx-® Analyzer offers automated interpretation, tracking, and documentation. Features increase transfusion patient safety while also providing seamless integration with laboratory workplace. Providing automation and workflow-enhancement features, analyzer delivers complete assay results and...
Read More »Immunetics, Inc. Names John Yonkin as CEO
Boston, Mass. - Immunetics, Inc., an innovative developer of state-of-the-art assay technology for infectious disease diagnosis and blood screening, today announced that the company's Board of Directors has appointed John Yonkin as Chief Executive Officer. Mr. Yonkin will assume the post of CEO effective December 1, 2012. He will also serve as a member of the Board of Directors. Mr. Yonkin brings...
Read More »Immunetics, Inc. Names John Yonkin as CEO
Boston, Mass. - Immunetics, Inc., an innovative developer of state-of-the-art assay technology for infectious disease diagnosis and blood screening, today announced that the company's Board of Directors has appointed John Yonkin as Chief Executive Officer. Mr. Yonkin will assume the post of CEO effective December 1, 2012. He will also serve as a member of the Board of Directors. Mr. Yonkin brings...
Read More »Immunetics Receives FDA Clearance for BacTx Rapid Test for Bacterial Contamination of Platelets
Boston, MA - Immunetics, Inc., has received U.S. Food and Drug Administration (FDA) clearance for its BacTx-® rapid test for bacterial contamination in platelet units, Andrew E. Levin, Ph.D., Immunetics Chief Executive Officer and Scientific Director, announced today. Immunetics' BacTx rapid test addresses the greatest infectious risk in transfusion today. An estimated 1 in 2,000 platelet units...
Read More »Immunetics Receives FDA Clearance for BacTx Rapid Test for Bacterial Contamination of Platelets
Boston, MA - Immunetics, Inc., has received U.S. Food and Drug Administration (FDA) clearance for its BacTxÃ-® rapid test for bacterial contamination in platelet units, Andrew E. Levin, Ph.D., Immunetics Chief Executive Officer and Scientific Director, announced today. Immunetics' BacTx rapid test addresses the greatest infectious risk in transfusion today. An estimated 1 in 2,000 platelet...
Read More »Immunetics, Inc. to Present Novel, Rapid Test for Bacterial Contamination of Platelets at American Association of Blood Banks (AABB) Annual Meeting
Boston, Mass. - October 18, 2011 - Immunetics, Inc. announced plans to present a novel, rapid test for bacterial contamination of platelets at the American Association of Blood Banks (AABB) Annual Meeting, Oct. 21st-25th, in San Diego. Bacterial contamination of platelets has been identified as the #1 infectious risk of transfusion, with approximately 1 out of 2,000 platelet units contaminated....
Read More »Immunetics, Inc. to Present Novel, Rapid Test for Bacterial Contamination of Platelets at American Association of Blood Banks (AABB) Annual Meeting
Boston, Mass. - October 18, 2011 - Immunetics, Inc. announced plans to present a novel, rapid test for bacterial contamination of platelets at the American Association of Blood Banks (AABB) Annual Meeting, Oct. 21st-25th, in San Diego. Bacterial contamination of platelets has been identified as the #1 infectious risk of transfusion, with approximately 1 out of 2,000 platelet units contaminated....
Read More »